CLTI

Drug-Eluting Resorbable Scaffold Maintains a 3-Year Patency Advantage Over Angioplasty in Infrapopliteal CLTI

Three-year LIFE-BTK data show sustained patency and reintervention benefits with a drug-eluting resorbable scaffold versus angioplasty in selected patients with infrapopliteal CLTI, with comparable limb salvage and safety.